Monthly research recap
Psilocybin research: September 2026
What September 2026's 25 new studies found, synthesized from the papers below. All Psilocybin research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, then ranked by relevance.
Research indexed in September 2026 on psilocybin is dominated by reviews, trial protocols, and preclinical work rather than completed definitive trials. Where controlled human data exist, they point to rapid symptom improvement in treatment-resistant depression and anorexia nervosa, but effects often wane over time and several trials miss primary endpoints or show no advantage over placebo at low doses. The main caveats are small samples, difficulty maintaining blinding, strict patient selection, and limited long-term durability data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Stroboscopic light stimulation as a controllable probe of the psilocybin state: a mechanistic framework and a falsifiable prediction 2026 | theoretical | Unclear | Argues that psilocybin's suppression of posterior alpha power and relaxation of high-level cortical priors may let frequency-controlled stroboscopic light modulate visual experience, predicting increased Visionary Restructuralization on the 5D-ASC relative to an arrhythmic control. | |
| Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT 2026 | cross-sectional survey | Unclear | Describes self-reported health outcomes attributed to recent use of psilocybin and other psychedelics, with no specific outcomes, comparisons, or effect sizes reported in the available text. | |
| Psilocybin Microdosing Schedules, 5-HT2A Adaptation, and the Age-Dependent Cortical State: From Intermittent to Continuous Exposure 2026 | theoretical | No effect | Argues dosing schedule should be an independent pharmacological variable, noting the first dedicated randomized trial in major depressive disorder (2 mg psilocybin once weekly) did not demonstrate superiority over placebo, leaving continuous daily exposure inadequately tested. | |
| Psilocybin and Contrasting Musical Compositions: Effects on Music-Evoked Emotional Responses in Healthy Adults 2026 | RCT | 36 | Supports | Psilocybin (0.26 mg/kg) increased wonder, transcendence, and joyful activation across both a classical and a psytrance composition, with a composition-by-condition interaction for sadness, suggesting limited interaction between drug and music. |
| Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male mice 2026 | preclinical animal study | Mixed | Psilocybin and ethocybin (3 mg/kg) given after Pavlovian aversion learning increased subsequent aversive memory expression (more freezing) in male mice, which the authors propose might increase psychotherapeutic accessibility of such memories in humans. | |
| Apomorphine and psilocybin to improve recovery from coma in the intensive care unit: protocol for a prospective, open-label, dose-escalation study. 2026 | clinical trial protocol | 80 | Unclear | Hypothesizes that combining apomorphine and psilocybin (1, 10, or 25 mg) is safe in ICU patients with disorders of consciousness and may reveal cerebral reserves, with time to awakening within 30 days as the primary outcome. |
| A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults 2026 | RCT | 56 | Supports | Low-dose oral psilocybin (0.5-4.0 mg) produced dose-related subjective effects distinguishable from placebo at 2.5 mg and above, with dose-dependent pupillary dilation but no cognitive impairment, no increase in state anxiety, and adverse events comparable to placebo. |
| Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants 2026 | RCT | 40 | No effect | Low-dose modified-release psilocybin (0.5-2.0 mg) produced predictable, dose-proportional psilocin exposure with low variability and no measurable psychoactive effects, with no serious adverse events or clinically meaningful treatment-related changes. |
| EFFICACY AND SAFETY OF PSILOCYBIN IN TREATMENT-RESISTANT DEPRESSION: A REVIEW 2026 | review | Supports | Concludes psilocybin with psychological support produces rapid, clinically significant reductions in depressive symptoms in treatment-resistant depression, with efficacy at least comparable to SSRIs and often faster onset, but notes large long-term trials are needed for durability. | |
| Exploring the Therapeutic Potential of Psilocybin: A Comprehensive Review of Clinical Trial Evidence and Implications for Rescheduling 2026 | review | Supports | Concludes psilocybin under structured psychotherapeutic supervision shows therapeutic potential across several psychiatric conditions, with controlled trials indicating lasting improvements in mood and quality of life and generally mild, self-limiting side effects. | |
| Perceptions and Attitudes on Psilocybin-Assisted Therapy among Underrepresented People with Cancer. 2026 | qualitative | 19 | Mixed | Participants held nuanced views of psilocybin-assisted therapy shaped by structural, cultural, and informational factors, ranging from viewing it as a legitimate structured intervention to uncertainty about its usefulness, with trust, safety, and cultural considerations affecting participation. |
| Psilocybin restores social novelty investigation in male SAPAP3 knockout mice and engages prefrontal–hippocampal circuitry 2026 | preclinical animal study | Supports | Psilocybin (1 mg/kg) produced a male-specific, enduring restoration of social novelty investigation in SAPAP3 knockout mice, with infralimbic cortex activation correlating with the behavioral improvement. | |
| Exploratory safety, tolerability, and feasibility of psilocybin-assisted psychotherapy for adults with co-occurring treatment-resistant depression and cluster B personality disorders 2026 | secondary analysis of a clinical trial | 10 | Supports | Mean MADRS scores declined from 30.4 pre-treatment to 22.3 at six months and mean suicidal ideation fell from 3.2 to 1.2, with substantial heterogeneity between individuals and no serious adverse events. |
| Psilocybin and ayahuasca in treatment-resistant depression: clinical evidence, methodological constraints and ethical challenges: a narrative review 2026 | narrative review | Supports | Reports that psilocybin and ayahuasca both show rapid reductions in depressive symptoms in treatment-resistant depression, with psilocybin having more robust evidence for sustained effects, but argues trials are constrained by strict selection, blinding difficulties, small samples, and ethical gaps. | |
| 5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice. 2026 | preclinical animal study | Supports | Psilocybin (2.5 mg/kg) facilitated fear extinction and increased BDNF and doublecortin-positive neurons even when the 5-HT2A receptor was blocked by ketanserin or MDL100907, indicating these effects are not dependent on 5-HT2A activation. | |
| Botanical Context Biasing for Experience-Dependent Neuroplasticity: A Two-Timescale Hypothesis of Directional Reinforcement During Psilocybin-Induced Plasticity 2026 | theoretical | Unclear | Proposes that companion botanicals co-formulated with psilocybin can bias the qualitative trajectory of the psychedelic state in reproducible, formulation-specific directions without increasing pharmacological intensity, operating across tonic and phasic timescales. | |
| [The use of psychedelics in psychiatry]. 2026 | review | Mixed | Argues psilocybin produces consistent, often large improvements in major depressive disorder and that a synthetic psilocybin met its primary endpoint in two phase 3 trials in 2025-2026, but contends certainty of evidence remains low or very low for several indications and that these should be considered experimental treatments. | |
| Psilocybin and Chronic Neuropathic and Centralized Pain: Converging Mechanisms in Central Sensitization, Neuroplasticity, and Network Organization 2026 | systematic review | Mixed | Concludes psilocybin should not be regarded as an established analgesic: preclinical results are mixed, with one rigorous null study finding no analgesic effect, and human evidence is limited to one small open-label fibromyalgia pilot, case reports, case series, and surveys. | |
| Multilevel Mechanisms and Clinical Efficacy of Psilocybin in Depression Treatment: A Systematic Review 2026 | systematic review | Supports | Reports that single or limited doses of psilocybin, particularly 25 mg, rapidly and sustainably reduce treatment-resistant depression symptoms, with efficacy comparable or superior to escitalopram, and proposes multilevel mechanisms including 5-HT2A activation, BDNF-TrkB signaling, hippocampal neurogenesis, and default mode network remodeling. | |
| What Is Psilocybin? 2026 | practical guide | Unclear | Provides patient-oriented information about psilocybin, describing its medical and recreational use and its potential side effects. | |
| 562. Repeated psilocybin administration does not induce rewarding effects and increases ventral tegmental dopaminergic activity during withdrawal 2026 | preclinical animal study | 38 | No effect | Repeated psilocybin (10 mg/kg) produced no conditioned place preference and no withdrawal-related behaviors, while psychedelic-associated and compulsive-like behaviors declined over the 7-day treatment, and VTA dopamine neurons showed increased activity 48 hours after the last dose. |
| Psilocybin selectively suppresses novelty-induced grooming via 5-HT2B receptors: A microstructure analysis in Wistar rats. 2026 | preclinical animal study | Supports | Psilocybin reduced novelty-induced grooming in Wistar rats, mainly by selectively suppressing abnormal, non-comfort grooming microstructure, and RS-127445 reversed this reduction, implicating 5-HT2B receptors. | |
| 701. Efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa: a proof-of-concept study 2026 | RCT | Mixed | COMP360 psilocybin (25 mg vs 1 mg) produced rapid improvement in Eating Disorder Examination global scores by Week 2 maintained to Week 12, but the between-group difference and effect size diminished over time, obsessive-compulsive symptoms showed only a moderate early effect, and weight change did not differ between groups. | |
| 643. A mechanism-informed clinical trial of psilocybin-assisted therapy for opioid use disorder: rationale and neurobiological framework 2026 | clinical protocol | Unclear | Proposes that psilocybin-assisted therapy may address reward dysregulation, anhedonia, and social functioning deficits not targeted by existing opioid pharmacotherapies, with time to return to opioid use as the primary outcome; no results are reported. | |
| Craving Reduction and Smoking Outcomes in Psilocybin-Assisted and Standard Cessation Care. 2026 | observational cohort | Mixed | Psilocybin-assisted care was associated with greater smoking reduction at week 12 and greater early reductions in urge, but was not associated with verified abstinence after adjustment; early craving reduction was associated with abstinence. |
Points of agreement
- Multiple reviews and trials report rapid reductions in depressive symptoms with psilocybin in treatment-resistant depression, often with onset faster than standard antidepressants.
- Low subperceptual doses of psilocybin show favorable safety and tolerability, with adverse events comparable to placebo and no cognitive impairment.
- Preclinical studies consistently show psilocybin modulates fear, social, and grooming behaviors, with several effects dissociable from 5-HT2A-mediated hallucinogenic activity.
- Reviews repeatedly note that blinding is difficult, samples are small, and patient selection is narrow, limiting generalizability.
Conflicts
- Some reviews describe psilocybin's antidepressant efficacy as comparable or superior to SSRIs, while another review notes that in the most rigorous trials the predefined primary endpoint does not always reach statistical significance and rates certainty of evidence as low or very low.
- One review concludes psilocybin is not an established analgesic with mixed preclinical results, contrasting with broader positive reviews of its therapeutic potential.
- A dedicated randomized trial of 2 mg psilocybin once weekly in major depressive disorder did not show superiority over placebo, while other reports describe robust antidepressant effects at higher doses.
- Anorexia nervosa trial results show early improvement that wanes over time, conflicting with claims of sustained benefit in depression reviews.
Gaps
- Long-term durability of therapeutic effects beyond 6-12 months is largely unestablished.
- Blinding integrity and expectancy effects remain unresolved across trials.
- Populations studied are narrow, excluding patients with comorbidities, high suicide risk, or polypharmacy, and underrepresented groups are rarely included.
- Optimal dosing schedules, including continuous versus intermittent microdosing, are inadequately tested.
- Human evidence in chronic pain, opioid use disorder, and disorders of consciousness is limited to protocols, small pilots, or case reports.
- Sex-specific and age-specific effects are suggested in preclinical work but not established in humans.